Logo for cyprumed

Cyprumed

Cyprumed is a drug delivery technology company based in Innsbruck, Austria. The company focuses on developing technology platforms for the oral administration of therapeutic peptides, including GLP‑1 analogues, macrocycles and mini-proteins. Cyprumed’s proprietary delivery platforms feature innovative tablet formulations that offer superior oral bioavailability and build on already approved pharmaceutical excipients, thus improving scalability, cost-efficiency and regulatory compliance. Cyprumed aims to transform peptide therapeutics by providing easy to manufacture, patient-friendly oral dosage forms. ​

Content by Cyprumed

Oral administration therapeutic medicine with many spilling white prescription medication isolated on white background
| 1 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D rendering illustrates a sandwich ELISA technique, where antigen detection is achieved between two layers of antibodies: a capture antibody and a detection antibody
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
Illustration of translucent Y-shaped antibodies floating in a soft blue and green background, representing antibody research, development, and biomedical science.
Explore how antibody accessibility and custom development strategies can influence the pace and success of translational research.
Digital illustration of a glowing DNA double helix surrounded by interconnected circuit-like lines on a dark blue background.
Learn the key differences between chemical and enzymatic approaches to synthetic DNA production and their implications for modern research.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue